Cargando…
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
BACKGROUND: Obesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. AIMS: To assess efficacy and safety of tofacitinib in patients with UC, by baseline body mass index (BMI). MET...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362064/ https://www.ncbi.nlm.nih.gov/pubmed/34165201 http://dx.doi.org/10.1111/apt.16439 |
_version_ | 1783738079189663744 |
---|---|
author | Farraye, Francis A. Qazi, Taha Kotze, Paulo G. Moore, Gregory T. Mundayat, Rajiv Lawendy, Nervin Sharma, Puza P. Judd, Donna T. |
author_facet | Farraye, Francis A. Qazi, Taha Kotze, Paulo G. Moore, Gregory T. Mundayat, Rajiv Lawendy, Nervin Sharma, Puza P. Judd, Donna T. |
author_sort | Farraye, Francis A. |
collection | PubMed |
description | BACKGROUND: Obesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. AIMS: To assess efficacy and safety of tofacitinib in patients with UC, by baseline body mass index (BMI). METHODS: This post hoc analysis evaluated patients with UC receiving placebo or tofacitinib from the 8‐week OCTAVE Induction 1 and 2 (NCT01465763, NCT01458951) and 52‐week OCTAVE Sustain (NCT01458574) studies. Patients were stratified by BMI at OCTAVE Induction 1 and 2 baseline (<25, 25 to <30 and ≥30 kg/m(2)). Outcomes included remission, endoscopic improvement, clinical response, sustained steroid‐free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form‐36 Health Survey scores. Adverse events were evaluated. RESULTS: At Week 8 of OCTAVE Induction 1 and 2, and Week 52 of OCTAVE Sustain, higher proportions of patients receiving tofacitinib 5 or 10 mg twice daily (b.d.) achieved clinical response vs placebo, regardless of baseline BMI subgroup (all P < 0.05). Proportions of patients achieving efficacy endpoints were generally similar across BMI subgroups; in univariate and multivariate regression analyses, BMI was not a significant predictor (all P ≥ 0.05; univariate BMI [continuous] odds ratio for remission: 0.98 [95% confidence interval 0.95, 1.02]). There was no consistent trend between BMI and adverse events. Among patients receiving tofacitinib 10 mg b.d. in OCTAVE Induction 1 and 2, serious infections were numerically greater in the BMI ≥30 subgroup (3.2%) vs other subgroups (0.4%). Limitations included small patient numbers in the BMI ≥30 subgroup. CONCLUSIONS: Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI. |
format | Online Article Text |
id | pubmed-8362064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83620642021-08-17 The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme Farraye, Francis A. Qazi, Taha Kotze, Paulo G. Moore, Gregory T. Mundayat, Rajiv Lawendy, Nervin Sharma, Puza P. Judd, Donna T. Aliment Pharmacol Ther Bmi and Tofactinib Efficacy in Uc BACKGROUND: Obesity may affect efficacy and safety of biologic treatments for ulcerative colitis (UC). Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. AIMS: To assess efficacy and safety of tofacitinib in patients with UC, by baseline body mass index (BMI). METHODS: This post hoc analysis evaluated patients with UC receiving placebo or tofacitinib from the 8‐week OCTAVE Induction 1 and 2 (NCT01465763, NCT01458951) and 52‐week OCTAVE Sustain (NCT01458574) studies. Patients were stratified by BMI at OCTAVE Induction 1 and 2 baseline (<25, 25 to <30 and ≥30 kg/m(2)). Outcomes included remission, endoscopic improvement, clinical response, sustained steroid‐free remission, Inflammatory Bowel Disease Questionnaire total score and Short Form‐36 Health Survey scores. Adverse events were evaluated. RESULTS: At Week 8 of OCTAVE Induction 1 and 2, and Week 52 of OCTAVE Sustain, higher proportions of patients receiving tofacitinib 5 or 10 mg twice daily (b.d.) achieved clinical response vs placebo, regardless of baseline BMI subgroup (all P < 0.05). Proportions of patients achieving efficacy endpoints were generally similar across BMI subgroups; in univariate and multivariate regression analyses, BMI was not a significant predictor (all P ≥ 0.05; univariate BMI [continuous] odds ratio for remission: 0.98 [95% confidence interval 0.95, 1.02]). There was no consistent trend between BMI and adverse events. Among patients receiving tofacitinib 10 mg b.d. in OCTAVE Induction 1 and 2, serious infections were numerically greater in the BMI ≥30 subgroup (3.2%) vs other subgroups (0.4%). Limitations included small patient numbers in the BMI ≥30 subgroup. CONCLUSIONS: Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI. John Wiley and Sons Inc. 2021-06-24 2021-08 /pmc/articles/PMC8362064/ /pubmed/34165201 http://dx.doi.org/10.1111/apt.16439 Text en © 2021 Pfizer Inc. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Bmi and Tofactinib Efficacy in Uc Farraye, Francis A. Qazi, Taha Kotze, Paulo G. Moore, Gregory T. Mundayat, Rajiv Lawendy, Nervin Sharma, Puza P. Judd, Donna T. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme |
title | The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme |
title_full | The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme |
title_fullStr | The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme |
title_full_unstemmed | The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme |
title_short | The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme |
title_sort | impact of body mass index on efficacy and safety in the tofacitinib octave ulcerative colitis clinical programme |
topic | Bmi and Tofactinib Efficacy in Uc |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362064/ https://www.ncbi.nlm.nih.gov/pubmed/34165201 http://dx.doi.org/10.1111/apt.16439 |
work_keys_str_mv | AT farrayefrancisa theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT qazitaha theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT kotzepaulog theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT mooregregoryt theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT mundayatrajiv theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT lawendynervin theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT sharmapuzap theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT judddonnat theimpactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT farrayefrancisa impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT qazitaha impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT kotzepaulog impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT mooregregoryt impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT mundayatrajiv impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT lawendynervin impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT sharmapuzap impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme AT judddonnat impactofbodymassindexonefficacyandsafetyinthetofacitiniboctaveulcerativecolitisclinicalprogramme |